Table 1 Clinical characteristics of the MGH and TARGET cohorts.
From: MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma
Cohort | MGH | TARGETa |
|---|---|---|
N | 74 | 95b |
Years collected | 1994–2013 | 2000–2012 |
before 2000 | 25 | 0 |
2000–2004 | 23 | 25 |
2005–2009 | 19 | 45 |
after 2009 | 7 | 22 |
Not available | 0 | 3 |
Age at Diagnoses (years) | ||
Median | 22.5 | 14.7 |
Range | 8–72 | 3–39 |
Sex (#/%) | ||
Male | 49/66 | 54/57 |
Female | 25/34 | 41/43 |
Tumor Location | ||
Axial | 2 | 5 |
Appendicular | 72 | 90 |
Upper | 7 | 7 |
Lower | 65 | 83 |
Histologic Subtype | ||
NOS | 42 | Not available |
Osteoblastic | 5 | |
Fibroblastic | 4 | |
Chondroblastic | 16 | |
Small Cell | 4 | |
Mixed | 3 | |
Metastases at Diagnoses (#/%) | ||
No | 57/77 | 71/75 |
Yes | 17/23 | 24/24 |
Chemotherapy regime | ||
MAP or AP | 29 | 17 |
MAP and other | 40 | 9 |
Other | 3 | 0 |
Not available | 2 | 69 |
Chemo-responsec | ||
Optimal | 25 | 22 |
Suboptimal | 26 | 30 |
Not available | 23 | 43 |
Events | ||
Deathsd | 28 | 37e |
Recurrences | 36 | 47f |
Follow Up Time (years) | ||
Median | 6.4 | 3.6 |
Alive at last follow up | 44 | 58 |
AWD | N = 11 | Not available |
Avg. Follow Up and range | 10.5 (4.3–19.0) | |
NED | N = 33 | Not available |
Median follow up and range | 11.2 (2.8–19.2) | |
